Atlassian Corporation (TEAM)

Atlassian is trading in a sharp drawdown after a steep one-month fall, even as the longer trend remains intact. The stock sits at $152.44, below its 50-day average of $193.74 but 27.58% above its 200-day average of $119.49. Analysts remain constructive: 27 of 33 rate it Buy, and the median 12-month target of $204.00 sits well above the current price. The gap between that optimism and a valuation that prices in very high expectations is the central tension for the stock now.

The stock closed at $152.44 after a 19.72% drop over one week and a 26.62% drop over one month, yet it is still up 89.08% over six months. The move is a sharp pullback inside a longer advance rather than a collapse of the trend. The price sits 21.32% below its 50-day average of $193.74 but 27.58% above its 200-day average of $119.49, and the 50-day average remains 62.14% above the 200-day average. That spread shows the longer uptrend has not broken, even though the short-term tape has turned hard against the stock. The 14-day RSI of 28.9 places the stock in the oversold zone, and the MACD line is negative, so momentum indicators agree that selling has been heavy. Last session's volume ran 26.3% below its average, so the latest bounce of 2.58% came on lighter trading.

Atlassian trades at a trailing P/E of 461.94, against a sector median of 35.1, which is at a premium to peers by any measure. Reported earnings per share over the last 12 months were $0.33, and the market capitalisation is $38.6B. The gap is about profit rather than revenue. The net profit margin is 1.28% and the operating margin is 10.65%, while return on equity of 7.75% trails the sector median of 13.4%. Debt-to-equity stands at 1.35. Investors are paying for expected growth, and the company's current profitability does not yet justify that price on its own.

For this fiscal year, analysts expect revenue of $7.4B, a 13.3% increase, but they forecast EPS of $5.45, a 6.9% decline. Analysts are still constructive: 27 of 33 rate the stock Buy, 6 rate it Hold and none rate it Sell. Three of the six actions listed for November 6 to November 9, 2026 were reiterations of Buy or Outperform ratings from Citigroup, Barclays, Jefferies, Truist Securities and Oppenheimer, and no firm in that list changed its view. Ratings from 27 of 33 analysts were Buy three months ago as well, so the consensus has not shifted in the recent period.

Over the last 18 months, insiders recorded 377 sales worth $449.5M and 4 open-market purchases worth $990K. Insider sales are often planned in advance or made to cover tax on vesting shares, so they carry less weight than purchases. The open-market buying is small next to the selling, and it does not change the valuation picture on its own.

The base case is that TEAM keeps trading in a wide range while it works back toward its 20-day and 50-day averages. Recovery toward the $185.41 to $193.74 zone would need steady trading volume and a calmer tape, since the stock's typical daily move is 4.24%. Analysts expect revenue to grow 13.3% this fiscal year, but they expect EPS to shrink 6.9%, so the margin story has to improve for the valuation to look less stretched. A sustained move above the 50-day average would strengthen the case that the sell-off was a reset within an uptrend. The lowest analyst target is $150.00, which is close to the current price. The median target of $204.00 is the analysts' figure, not a forecast from CleaRank.